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Abstract
Background: Rates of medication non-adherence in dialysis patients are high, and improving adherence is likely
to improve outcomes. Few data are available regarding factors associated with medication adherence in dialysis
patients, and these data are needed to inform effective intervention strategies.
Methods/design: This is an observational cross-sectional study of a multi-ethnic dialysis cohort from New Zealand,
with the main data collection tool being an interviewer-assisted survey. A total of 100 participants were randomly
sampled from a single centre, with selection stratified by ethnicity and dialysis modality (facility versus home). The
main outcome measure is self-reported medication adherence using the Morisky 8-Item Medication Adherence
Scale (MMAS-8). Study data include demographic, clinical, social and psychometric characteristics, the latter being
constructs of health literacy, medication knowledge, beliefs about medications, and illness perceptions. Psychometric
constructs were assessed through the following survey instruments; health literacy screening questions, the Medication
Knowledge Evaluation Tool (Okuyan et al.), the Beliefs about Medication Questionnaire (Horne et al.), the Brief Illness
Perception Questionnaire (Broadbent et al.). Using the study data, reliability analysis for internal consistency is
satisfactory for the scales evaluating health literacy, medication knowledge, and beliefs about medications, with
Chronbach’s α > 0.7 for all. Reliability analysis indicated poor internal consistency for scales relating to illness
perceptions. MMAS-8 and all psychometric scores are normally distributed in the study data.
Discussion: This study will provide important information on the factors involved in medication non-adherence
in New Zealand dialysis patients. The resulting knowledge will inform long-term initiatives to reduce medication
non-adherence in dialysis patients, and help ensure that they are addressing appropriate and evidence based
targets for intervention.
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Background
Adherence of patients to prescribed medications is an issue
of concern to payers, policymakers, providers and health-
care professionals. Non-adherence is highly prevalent [1],
expensive to health systems [2], and associated with poorer
outcomes for many chronic diseases [3–5].
In patients with end stage kidney disease, dialysis is an
effective treatment for the removal of most uremic toxins,
although the majority of patients require a large number
of additional medications to control hyperphosphatemia,
hypertension, anaemia and other biochemical conse-
quences of their disease. Furthermore, patients often have
other comorbid conditions that require treatment. The
total drug burden in dialysis patients can be considerable,
with the median number of prescribed tablets per day
ranging from 12 to 19 in recent observational studies, the
highest burden of any chronic disease group [6, 7]. Medi-
cation non-adherence within this group is unsurprisingly
high (Table 1). A recent systematic review of the literature
appraised 19 widely divergent studies, and reported the
prevalence of non-adherence to be between 3 to 80 %
(depending on definition), with a median of 50 % [8]. In a
previous pilot study into medication non-adherence
among haemodialysis patients at our institution, non-
adherence rates were 33 % and several fold higher
amongst New Zealand (NZ) Māori, Pacific Peoples and
the elderly [9].
The consequences of medication non-adherence have
not been well established in dialysis populations. Most in-
vestigators infer changes in relative mortality risks from
suboptimal blood pressure (non-adherence to antihyper-
tensives), suboptimal serum phosphate (non-adherence to
phosphate binders), and suboptimal haemoglobin (non-
adherence to erythropoietin). Perhaps the most compel-
ling data, however, can be found in a recent study aiming
to reduce medication-related problems in haemodialysis
patients through an integrated pharmacy program in a
large United States dialysis organization. In a retrospective
analysis, the mortality risk with an integrated pharmacy
program (versus none) was 0.79 (95 % CI, 0.74-0.84), rela-
tive rate of hospital admission 0.93 (95 % CI, 0.90-0.96),
and relative number of hospital days 0.86 (95 % CI,
0.82-0.90) [10]. There is therefore a strong signal that
improved medication adherence might result in clinical
benefits for the patient, and lower healthcare resource
utilization for the country.
In other patient groups interventional strategies to
improve medication adherence have been validated [11],
but information specific to dialysis patients is lacking
[12]. A major barrier to designing strategies to improve
medication adherence in dialysis patients is the lack of
knowledge about factors associated with adherence to
drugs within this group. Demographic factors, clinical
factors and psychosocial factors may all influence medica-
tion adherence, but whether these are important in dialy-
sis patients is unclear [13]. There is therefore an exigent
need to clarify the drivers of poor medication adherence
in this patient group, to inform interventions and optimize
their chances of being effective.
In this article, we describe the protocol for an observa-
tional study of medication adherence in a large multi-
ethnic New Zealand cohort, in which we are studying
self-reported medication adherence in relation to a variety
of demographic, clinical, social, and psychometric factors.
Of note, the psychometric constructs used for this study -
and the instruments with which they are assessed – are
not well-described in dialysis populations, and distribution
of construct scores and the reliability of the instruments
cannot be assumed. As part of this article, therefore, we
perform and report an interim analysis of the completed
study dataset, with a view to ensuring appropriate use of
these data in our subsequent statistical modelling.
Methods/design
Study aim and hypothesis
The broad aim of this study is to improve our understand-
ing of the factors involved in medication non-adherence
in dialysis patients, to inform the development of an inter-
vention strategy. The specific objectives are to estimate
self-reported medication adherence in this population,
and explore the relationship between this outcome and
patients’ medication knowledge and beliefs, health literacy,
Table 1 Recent studies of drug non-adherence rates in dialysis populations
First author of study (year) Drug/treatment studied Patient group Rate of non adherence Significant correlations
Martins (2013) Phosphate binders Haemodialysis (502 patients) 65.7 % Cerebrovascular disease,
higher PTH, comprehension,
side effects





Oral medications Haemodialysis (19 studies included) 67 % (range 3–80)
Karamanidou (2008)
Systematic review
Phosphate binders Dialysis (34 studies included) Mean 51 % (range 22-74 %) Younger age, psychosocial
beliefs
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and illness perceptions. As part of the study, we will
explore differences in these relationships by age, ethnicity,
dialysis modality (facility based dependent versus home-
based independent), and dialysis vintage (duration on
dialysis since dialysis inception).
Study design
This is a cross-sectional study of a sample of prevalent
dialysis patients from a single centre.
Demographic and clinical study data were collected
from patients’ clinical records (see case report form in
Additional file 1), and directly from participant records
in the Australia and New Zealand Dialysis and Transplant
Registry (www.anzdata.org.au). Patient perceptions and
beliefs were assessed using survey instruments adminis-
tered as an in-person, interviewer-assisted questionnaire
(see Additional file 2). As the interviews were not audio-
recorded, they were conducted with pairs of interviewers
for quality control purposes. Where possible, interviews
were conducted in English, but professional interpreters
were used if needed in the hospital setting.
The medication discussed in relation to the study was
either a self administered erythropoiesis-stimulating agent,
an angiotensin converting enzyme inhibitor, or a phos-
phate binder, depending on each participant’s medication
regimen.
Data collection was undertaken from 19th July 2013 to
13th June 2014, with database lock on 9th November 2014.
Setting
The study setting is the Counties Manukau District
Health Board (CMDHB) in Auckland, New Zealand.
This is the largest dialysis programme in New Zealand,
and provided care at the time of the study to approxi-
mately 550 patients, or 22 % of that country’s entire dialysis
population [14]. The dialysis population reflects the
general population, which is multi-ethnic with a high
proportion of NZ Māori and Pacific Peoples, and socioeco-
nomically disadvantaged (www.cmdhb.govt.nz). The preva-
lence of home dialysis is high in the programme, and 31 %
of dialysis patients are on peritoneal dialysis (PD) and 18 %
are on home haemodialysis (HD).
Target population and eligibility criteria
Eligible participants were those with end stage renal
disease undergoing dialysis at CMDHB aged ≥16 years
old. Exclusion criteria include patients posing logistic or
safety risks to interviewers; those suffering acute severe
medical illness; those with severe communication difficul-
ties (dysphasia, severe hearing impairment etc.); those
who were unable to give direct informed consent.
Recruitment of participants
Participant selection was by computer-generated random
selection from the service census. Selection was stratified
by two factors to generate equally sized groups within 6
classifications, as defined by the following strata: recorded
ethnicity from clinical records (NZ Māori versus Pacific
Peoples versus “other” ethnicity), and location of dialy-
sis (in a facility [in-centre HD] versus at home [home
HD or PD]).
Power calculations
A formal sample size was not calculated for this
project, given the exploratory nature of the study. How-
ever, the rule of thumb to determine ratio of cases (N)
to instrumental variables (m) is N > 50 + 8(m), subject
to other factors such as alpha level and expected effect
sizes [15, 16]. Given the planned statistical approach, it
was anticipated that a sample size of 100 participants in
total would provide adequate power for most aspects of
analysis.
Research outcomes and endpoints
The main outcome is self-reported medication adher-
ence, as measured by the Morisky 8-Item Medication
Adherence Scale (MMAS-8) [17]. This scale is a reli-
able and validated instrument, and is one of the most
widely used tools to assess patient adherence [18–20].
It comprises eight items that address medication taking
behaviour and (intentional and unintentional) adher-
ence. The first seven items in the scale have dichotom-
ous responses (yes/no), and the eighth item has 5 point
Likert scale response, from 1 = never to 5 = all the time.
The MMAS-8 score ranges from 0 to 8. Those who
score less than 6 are considered to have low adherence,
and those who score 6 or 7 are considered to have
medium adherence, and those who score 8 high
adherence.
Quantitative variables
The following demographic and clinical data were
collected:
1) Demographics: We collected data about age, gender,
ethnicity (prioritised according to accepted ethnicity
data protocols [21–23]), relationship status, home
ownership, and household composition, based on
questions from the 2006 Statistics New Zealand
Census. We assessed the socioeconomic status of
the patient cohort using the NZDep score, which
combines nine variables from the census that reflect
eight domains of deprivation (income, home
ownership, social support, employment, academic
qualifications, living space, access to a telephone,
access to a car). The index provides a score for each
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meshblock in New Zealand, which are defined
geographical areas defined by Statistics New Zealand
containing a median number of approximately 87
people in 2006. The NZDep score divides New
Zealand into deciles, e.g. a value of 10 indicates the
meshblock is in the most deprived 10 % of the New
Zealand population, and a value of 1 indicates that
the meshblock is in the least deprived [24].
2) Clinical characteristics: We collected data about
current modality of dialysis, dialysis vintage, history
of previous transplantation, current dialysis dose
(expressed as single pool Kt/V), age-adjusted Charlson
Co-morbidity Index [25, 26], cause of end stage kidney
disease, presence of diabetes mellitus, coronary artery
disease, cerebrovascular disease, peripheral vascular
disease, and lung disease.
The following study data were collected to evaluate
the following psychometric constructs - health literacy,
medication knowledge, beliefs about medication, and
illness perceptions:
1) Health literacy: We assessed health literacy using a
combination of three separate, single-item instruments
(see Additional file 2, sections F and G). Each of these
instruments has been validated against the S-TOFHLA
(Short Test of Functional Health Literacy in Adults)
and REALM (Rapid Estimate of Adult Literacy in
Medicine) in the general population, and to a lesser
degree the dialysis population [27, 28]. The
combination of three instruments has been used
successfully with health literary assessments in a
number of studies [29], including a large one of 1796
Veterans Administration patients [30]. We have
previously assessed the validity and reliability of
combining the three instruments in this study sample,
supporting the use of the average of the individual
scores as a single health literacy construct [31]. Those
who score three or above on the final combined
scale are considered to have marginal or poor
health literacy.
2) Medication knowledge: We assessed patients’
knowledge of medications using the Medication
Knowledge Evaluation Tool (MKET), an instrument
based on the work of McPherson [32], which has
been subsequently adapted by Okuyan [33, 34]
(see Additional file 2, section B). Knowledge is
measured with 7 items, covering medications’
names, intended purpose, intended regimen,
intended route of administration, possible side
effects, and course of action if side effects occur or a
dose is missed. The final score is a summation of
seven subscales measured on a 0 or 1 ordinal scale.
High medication knowledge is defined as a score ≥ 5.
3) Beliefs about medication: We assessed patients’
perceptions and expectations about their
medications using the Beliefs about Medication
Questionnaire (BMQ) [35–38] (see Additional file 2,
section D). The BMQ contains two separate
constructs (generically referred to as the BMQ-
Specific subscales), namely the Medication Concerns
construct and the Medication Necessity construct.
The former represents the concerns of patients around
the negative effects for taking their medication, and
the latter their beliefs around the necessity of taking it
to maintain health. These constructs are sometimes
presented as a ratio or differential, although we
chose to analyse them separately in this study. The
Medications Concerns construct is measured with
5 of the BMQ items (e.g., “I sometimes worry about
the long-term effects of my medicines”, “My
medicines disrupt my life”), and the Specific
Necessity construct with another 5 items
(e.g., “My health, at present, depends on my
medicines”, “Without my medicines I would be
very ill”). Items are rated on 5 point subscales,
from 1 = strongly disagree to 5 = strongly agree. A
combined high score in the Medications Concerns
construct theme means that patients are worried
about potential adverse effects of their medications.
Conversely, a combined high score in Specific
Necessity construct means that patients think their
medications are important to them. An additional
statement of concern (not included in the Specific
Concern construct) is included in the BMQ that
asks patients whether they believe their medications
to be causing unpleasant side effects, also rated on
a 5 point subscale.
4) Illness perceptions: We assessed patients’ perceptions
about their health problems using the Brief Illness
Perception Questionnaire (BIPQ), an instrument based
on the work of Weinman [39] and then Moss-Morris
[40], later adapted by Broadbent [41] (see Additional
file 2, section E). The BIPQ is a 9-item scale, assessing
illness perceptions across 4 interrelated dimensions:
cognitive illness representations (items 1–5), emotional
illness representations (items 6–8), illness
comprehensibility (item 7) and causal
representation (item 9). Items are rated on an
11-point Likert-like scale. The BIPQ can be scored
in multiple ways, as individual items, as a score
within each of the 4 dimensions, or as a total score
[41–43]. In the case of scoring, subscales relating to
items 3, 4, and 7 should be reversed (Personal
communication E Broadbent 15 Jan 2015).
5) Additional qualitative questions were incorporated to
supplement some of the study aims (see Additional
file 2, Section H). These questions were developed
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after a literature review, brainstorming by the
research team, and discussions with nephrology
healthcare professionals within the CMDHB
programme.
Reliability of study instruments
We assessed the reliability of the psychometric instru-
ments by their internal consistency. Internal consistency
was defined by the Cronbach’s α statistic, using a score
of 0.7 or larger as indicative of a strong level of internal
consistency amongst items in the scale, and a score
of <0.5 as being indicative of poor internal consistency
[44]. Results of the reliability analysis are reported in
Table 2. The Cronbach’s α for item subscales within
medication adherence, BMQ-specific medication neces-
sity, BMQ-specific medication concerns, and health liter-
acy were 0.77, 0.71, 0.78, and 0.78 respectively. This is
indicative of strong level of internal consistency amongst
subscales, and supports the retention of all items within
each construct. The Cronbach’s α for the subscales within
medication knowledge, however, was 0.44 due to the out-
lying item B7 (See Additional file 2, Section B). By drop-
ping this item from the construct, the Cronbach’s α
improved to 0.63, which is closer but nonetheless slightly
short of the suggested threshold of 0.7. Despite this
marginal internal consistency, a considered judgement
was adopted to retain all times in the construct other than
for B7. Additionally, Nunally provides support a threshold
for Cronbach’s α above 0.6 as being acceptable in the case
of an exploratory study [45].
The internal consistency of the subscales for the BIPQ
emotional and cognitive dimensions were poor, although
the reliability of subscales within the cognitive dimen-
sion improved a little by dropping the outlying items E2
and E4 (See Additional file 2, Section E). Even after these
manoeuvres, however, Cronbach’s α did not reach the
acceptable threshold of 0.6.
Distribution of scores for psychometric constructs
We assessed the scores from the MMAS-8 and psycho-
metric constructs for normality, skewness and kurtosis. A
strictly quantitative description of the various scores is pro-
vided in Table 3, without any accompanying interpretation
or insights. Inspection of the z-scores for both the kurtosis
criteria suggest the scores are well within the +/−1.96 cut-
off points (p ≤ 0.05) for normality [46]. The z-scores for
skewness are below the +/−1.96 (p ≤ 0.05) criteria for the
knowledge and concerns scores, while the necessity and
total adherence scores for skewness are below the +/−2.58
cut-off (p ≤ 0.01). Since a sample of 100 fits within the
guideline of a small sample, the skewness scores suggest
that the dataset is borderline but acceptable for least
squares regression, especially in the context of multivariate
data analysis [47].
Statistical analysis
Simple comparisons will be made by Chi-square test,
Student’s t-test or their non-parametric equivalents as
appropriate. Exploratory modelling will be performed
using multivariate regression analysis, using a number of
specific techniques. These will include conventional
regression analysis, and also mediation, moderation, and
conditional process analysis (see an example in Fig. 1)
[48]. Scores for psychometric constructs can be mod-
elled as either continuous variables (where higher scores
indicate stronger beliefs or perceptions in the construct
represented by the scale), or by dichotomizing at the
scale midpoint or some other point of discrimination
[37]. While the latter is a convenient way of categorizing
respondents, we will attempt to use the continuous scale
analyses as this provides richer information that is lost
when scales are dichotomized. Statistical significance of
associations will be attributed to findings if the two-
tailed P value is <0.05.
Qualitative data will be analyzed using a general
inductive/thematic approach [49].
Ethical considerations
The study protocol has been reviewed and approved by
the National (NZ) Health and Disability Ethics Committee
(IORG0000895) and the Counties Manukau Institutional
Review Board (FWA00021560), and the University of
Auckland Human Participants Ethics Committees
(IRB00009352). Informed consent was gained from all
participants.
Discussion
This study will provide important information on the fac-
tors involved in medication non-adherence in New Zealand
dialysis patients. The resulting knowledge will inform long-
term initiatives to reduce medication non-adherence in
dialysis patients, and help ensure that they are addressing
appropriate and evidence based targets for intervention.
Important strengths of this study include the use of
well-validated study instruments, and a study sample
that is inclusive of different ethnicities and importantly
modalities/locations of dialysis. These will allow us to
model links between demographics, environment, and
psychometric characteristics when assessing their indi-
vidual effects on medication adherence. However, there
are several limitations of this study. Firstly, the study
design is based upon interviewing each patient about
one medication that they are taking, a pragmatic
compromise that was accepted by the research team
given the diversity of different medication regimens in
the study sample. It is possible that adherence will differ
between different types of medication, which is some-
thing that cannot be assessed in this study, and could
conceivably be a source of unmeasured confounding.
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Medical Adherence Cronbach’s α = 0.77 C1 5.08 3.43 0.57 0.40 0.72
C2 4.79 3.58 0.49 0.27 0.74
C3 4.66 3.90 0.39 0.28 0.75
C4 4.79 3.66 0.44 0.25 0.75
C5 4.53 4.17 0.40 0.19 0.76
C6 4.63 3.71 0.56 0.41 0.73
C7 4.76 3.76 0.40 0.21 0.75
C8 4.91 3.50 0.51 0.39 0.73
Health Literacy Cronbach’s α = 0.78 F1 5.45 7.62 0.62 0.39 0.70
F2 4.84 7.69 0.60 0.36 0.72
F3 5.45 8.23 0.64 0.41 0.69
Medication Knowledge (Original)
Cronbach’s α = 0.44
B1 4.45 0.90 0.27 0.39 0.37
B2 4.14 0.91 0.26 0.18 0.38
B3 3.83 1.15 0.51 0.62 0.34
B4 3.86 1.12 0.36 0.51 0.36
B5 4.69 1.08 0.33 0.24 0.35
B6 3.90 1.03 0.42 0.35 0.31
B7 3.90 1.60 −0.39 0.24 0.63
Medication Knowledge – (Modified, B7
omitted) Cronbach’s α = 0.63
B1 3.55 0.97 0.41 0.28 0.57
B2 3.24 1.05 0.32 0.16 0.62
B3 2.93 1.35 0.48 0.62 0.58
B4 2.97 1.32 0.35 0.51 0.59
B5 3.79 1.24 0.37 0.24 0.58
B6 3.00 1.21 0.42 0.35 0.57
Beliefs about Medication - Medical Necessity
Cronbach’s α = 0.71
D1 16.93 5.96 0.42 0.23 0.73
D3 17.20 4.12 0.61 0.40 0.66
D4 16.87 5.39 0.47 0.33 0.71
D7 17.06 5.27 0.58 0.38 0.67
D10 16.94 6.06 0.51 0.31 0.70
Beliefs about Medication - Medical Concerns
Cronbach’s α = 0.78
D2 11.27 13.57 0.54 0.33 0.74
D5 10.67 12.47 0.61 0.40 0.72
D6 11.05 13.89 0.49 0.27 0.76
D8 11.46 14.09 0.54 0.30 0.74
D9 10.91 13.92 0.60 0.36 0.73
Illness Perception – Cognitive (Original)
Cronbach’s α = 0.41
E1 18.9 37.4 0.31 0.16 0.28
E2 17.0 46.6 0.10 0.04 0.44
E3a 22.2 32.4 0.38 0.16 0.20
E4a 24.9 52.7 0.03 0.04 0.45
E5 20.2 37.0 0.22 0.11 0.36
Illness Perception – Cognitive (Modified, E2
omitted) Cronbach’s α = 0.44
E1 10.1 29.5 0.30 0.15 0.32
E3a 13.4 24.9 0.37 0.15 0.22
E4a 16.1 43.5 0.02 0.04 0.52
E5 11.4 26.5 0.29 0.09 0.33
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Secondly, the sample size is modest, especially given the
diversity of the sample population. Notwithstanding, 100
participants is probably adequate given the novel regres-
sion techniques that are planned, where we will model 3
or 4 variables as either instrumental or mediating factors,
and the rest as effect modifiers. Finally, the qualitative in-
terviews were not recorded because of feasibility/resource
constraints, and also because this part of the study was to
supplement study aims that (in the great majority) were
being addressed by the survey tool. In an ideal world, ver-
batim transcription of recorded interviews would be
undertaken, as is the standard recommended practice.
This compromise can be expected to reduce the strength
and number of insights from the qualitative portion of the
study.
Patient-related factors are well known to influence
medication adherence. Some of these factors are purely
unintentional; such as personality, attentional and coping
style, comprehension difficulties, access to medications
etc. [50, 51]. Other factors are intentional, and some of
these relate closely to patient perceptions (Table 4).
Patients’ pre-existing beliefs about illness and medical
treatment are likely to affect their motivation to adhere to
prescribed treatment [40]. Traditionally research has
focused on perceptions of the need for treatment and
concerns about potential adverse effects (the necessity-
concerns framework) [52]. Within this framework, a
stronger perception of necessity for treatment is associ-
ated with higher adherence across disparate patient
groups with chronic diseases. Similarly, fewer concerns
about treatment are also associated with greater adher-
ence [52, 53]. These perceptions may be influenced by
factors such as ethnicity and cultural beliefs, [54] health
literacy and other psychosocial factors [13]. Limited health
literacy is particularly widespread in dialysis patients, and
Table 2 Internal consistency of construct item subscales (Continued)
Illness Perception – Cognitive (Modified, E4
omitted) Cronbach’s α = 0.45
E1 18.1 32.9 0.37 0.14 0.28
E2 16.1 43.5 0.09 0.04 0.52
E3a 21.3 30.4 0.35 0.13 0.28
E5 19.3 33.5 0.23 0.11 0.41
Illness Perception – Cognitive (Modified, E2
and E4 omitted) Cronbach’s α = 0.52
E1 9.2 25.4 0.35 0.13 0.38
E3a 12.5 23.2 0.34 0.12 0.41
E5 10.5 23.3 0.31 0.09 0.46
Illness Perception – Emotional Cronbach’s
α = 0.52
E6 5.90 10.1 0.35 0.12 n/a
E8 6.90 12.0 0.35 0.12 n/a
aScale reversed for these items (Personal communication E. Broadbent 15 Jan 2015
Table 3 Summary of scores for the final constructs of medication
adherence, medication knowledge, health literacy, beliefs
about medication, and illness perception, reported as mean
(standard deviation)
Construct Score
Medication adherence 5.5 (2.2)
Medication knowledge 4.3 (1.5)
Health literacya 2.6 (1.3)
Beliefs about medication (BMQ)
Medication necessity 21.3 (2.8)
Medication concerns 13.8 (4.5)
Illness perception (BIPQ)b
Cognitive dimension 32.2 (5.6)
Emotional dimension 12.8 (5.5)
Illness comprehensibility 2.02 (2.8)
aIncomplete data for 1 patient - excluded
bIncomplete data for 3 patients - excluded
For BIPQ cognitive dimension, two item subscales (E3 & E4) were reversed for
scoring. For illness comprehensibility, one item subscale (E7) was reversed for
scoring (Personal communication E. Broadbent 15 Jan 2015)
a)
b)
Fig. 1 Examples of extended regression analyses planned for these
study data. Panel (a) exemplifies conventional regression analysis,
and panel (b) exemplifies mediation regression analysis
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associated with reduced access to healthcare [55, 56].
Health literacy is a direct and indirect determinant of
medication adherence, and improving literacy may af-
ford clinician better opportunities to communicate with
patients about their medication [57, 58]. The impact of
environmental factors, for instance the location and
modality of dialysis, are not as well understood in
regards to the extent to which they influence medica-
tion adherence [59, 60]. In general, environmental
factors are potentially more amenable to modification
than patient factors, and are therefore important to in-
vestigate. Despite this, interventions to improve medi-
cation adherence often address patient-related barriers,
and less often condition, therapy, and socioeconomic
factors [61]. For instance, medication reconciliation
exercises often stall at initiation, as patients are unable
to recall the names of their medications. A potentially
inexpensive strategy for this problem may be to simplify
medication names to improve pill identification [62].
There is limited evidence for strategies to improve
adherence to therapy in dialysis patients. In a systematic
review of trials to improve general adherence to treat-
ment in haemodialysis patients, Matteson and Russell
summarized 8 trials, finding that 6/8 trials found modest
improvements in adherence with intervention, and that
most successful interventions relied on cognitive or
cognitive/behavioural intervention strategies [12]. Over-
all evidence was however limited by small sample size,
homogenous samples, short intervention periods and a
high baseline rate of poor adherence.
Current health outcomes for patients on dialysis are
significantly poorer than that of the general population,
with a median survival after dialysis inception of 4.2
years in New Zealand [63] and a significantly impaired
quality of life [64]. Given the high prevalence of medica-
tion non-adherence in dialysis patients and the potential
for improved outcomes [10], improving our knowledge
about factors involved in medication adherence in these
patients is of vital importance.
Additional files
Additional file 1: Clinical Data Case Report Form Version 1.1
29.04.2013.
Additional file 2: In-person, interviewer-assisted questionnaire.
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